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Abstract
Background: Although joint involvement is the second most common clinical manifestation after skin involvement
in patients with Henoch-Schönlein purpura (HSP), it has not been well characterized. The aim of this study was to
profile the clinical characteristics and identify the potential risk factors for kidney damage in HSP patients having
joint involvement.
Methods: We retrospectively reviewed 71 cases of HSP patients with joint involvement who attended our hospital
between January 2010 and March 2012 and analyzed their epidemiological profile, clinical characteristics, follow-up
findings (up to three years) and overall prognosis. Logistic regression analysis was performed to identify risk factors
associated with renal symptoms in HSP patients with joint involvement.
Results: Average age of patients was 8.55 ± 2.13 years with male to female ratio at 1.29:1. The peak age of disease
onset was six to 11 years. The most common triggers included upper respiratory infection, vigorous physical
activity, and autumn and winter seasons. Forty cases (56.35 %) had gastrointestinal involvement and 37 (52.11 %)
had kidney damage; gastrointestinal system, scrotal involvement, and increased D-dimer levels were significantly
associated with kidney injury (P < 0.05) by multivariate analysis. Glucocorticoid therapy was effective in alleviating
symptoms.
Conclusion: Gastrointestinal symptoms, scrotal involvement, and increased D-dimer are the potential risk factors for
kidney damage in HSP patients having joint involvement. Rational use of corticosteroids was probably responsible
for the good clinical outcomes.
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Background
Henoch-Schönlein purpura (HSP) is the most common
form of vasculitis in children. The condition has been
known for nearly 200 years. The estimated annual inci-
dence of HSP in China is 14.06 cases per 100,000 children
[1] with an increasing trend observed over successive
years, however, this rising trend has recently tapered,
possibly due to changes in social, economic, health, and
environmental conditions [2]. Factors triggering HSP
include infections (mainly upper respiratory infection),
drugs, food, insect bites and vaccination. Physical condi-
tions, such as exposure to cold are also known to be envir-
onmental triggers for the disease onset. The pathogenesis
of HSP is related to aberrant deposition of IgA-containing
immune complexes [3], which typically affects skin, gut,
joints and glomeruli. Among these, complications resulting
from kidney lesions are the most severe. Isolated micro-
scopic haematuria and minimal proteinuria are common
occurrences in children, with nephrotic syndrome and
renal dysfunction also being observed occasionally. The
prognosis is, to a large extent, dependent on the severity of
renal involvement [4–6].
However, the incidence of joint involvement in HSP
patients could be as high as 78 % [7], which is the sec-
ond most common feature after dermal manifestations
[6, 8]. Joint manifestations in HSP tend to be neglected
due to their mild nature. Moreover, atypical cases are
liable to be misdiagnosed and mistreated. With the
incidence increasing, investigation of every potential case
and assessment of renal involvement in these patients is
important for the successful management of HSP. With
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the aim of expanding our knowledge about HSP with
joint involvement, we retrospectively reviewed the
clinical characteristics, prognosis and kidney damage in
these HSP patients with joint involvement.
Methods
Patient characteristics
A total of 71 patients with HSP who attended the
Department of Dermatology at Dongying Hospital,
Shandong Province, between January 2010 and March
2012 were included in this study. The patients were evalu-
ated retrospectively. The diagnosis of HSP was based on
European League against Rheumatism (EULAR) endorsed
consensus criteria for HSP classification [7]. All cases de-
veloped skin purpura, acute arthritis or acute arthralgia,
accompanied with: (1) abdominal pain: diffuse colicky
pain. Some patients had gastrointestinal bleeding and em-
esis. (2) histopathology: proliferative glomerulonephritis
with predominant IgA deposit or typically leucocytoclastic
vasculitis with predominant IgA deposit. (3) renal involve-
ment: proteinuria > 30 mmol/mg of urine albumin/cre-
atinine ratio on a spot morning sample or >0.3 g/24 h;
presence of red blood cell casts or haematuria; red blood
cells casts in the urinary sediment or > 5 red blood cells/
high power field or ≥ 2+ on dipstick. Arthritis was defined
as arthralgia with limited movement or joint swelling.
Arthralgia was defined as joint pain without joint limited
movement or swelling.
The inclusion criteria were as follows: (1) age < 14 years
old; (2) no history of allergic or hematological disorders;
(3) not diagnosed with systemic lupus erythematosus,
renal or any other immunological disorders; (4) no active
infections such as tuberculosis, hepatitis B and other
contagious diseases. The exclusion criteria were: (1)
patients with incomplete information; (2) patients unable
to comply with the treatment; (3) patients with severe
heart, liver, lung, kidney or other organ system diseases.
A total of 131 HSP patients were admitted to our
hospital between January 2010 and March 2012. Of
these, 79 cases of HSP had joint involvement and were
thus considered for inclusion in this study. Among them,
two patients were found to be older than 14 years old
(41 and 16 respectively), one case had hypothyroidism,
and four patients had incomplete data (of these, one was
admitted to another hospital, and three patients were
lost to follow up). Thus, a total of 71 cases were finally
included in the study. The study was approved by the
Ethics Committee at the Dongying Hospital.
Laboratory investigations
All patients underwent laboratory tests such as antinu-
clear, anti-DNA, anti-ENA antibodies, routine blood and
urine tests, fecal occult blood, coagulation profile, anti-
streptolysin O titers, C-reactive protein, levels of C3,
IgA, IgG, IgM, D-dimer, BMI value, blood pressure, liver
function (ALT, AST), kidney function (SCr, BUN) and
joint x-ray.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation (SD) or median (interquartile range). Categor-
ical variables were expressed as percentages. Inter-group
differences on univariate analysis were evaluated by χ2
test. Multivariate logistic regression analysis was per-
formed to determine odds ratio at 95 % confidence
interval (CI). All statistical analyses were performed




A total of 71 cases including 40 males and 31 females
were included. The ratio of male to female was 1.29:1.
The average age was 8.55 ± 2.13 years and median age
was eight. Sixty- one cases (86 %) had peak age for dis-
ease onset between six and 11 years, with male to female
ratio of 1.22:1 (Fig. 1). As shown in Fig. 2, disease onset
occurred during all the seasons, with the highest
incidence being reported during autumn and winter
seasons (70 %). Respiratory tract infection was the most
frequent predisposing factor followed by vigorous
exercise, with 66 cases (93 %) being aware of the trigger
factors (Fig. 3).
Clinical manifestations
Main clinical features of the 71 HSP children were sum-
marized in Table 1. All 71 cases had typical skin manifes-
tations such as petechiae and ecchymosis. In 64 cases
(90 %), skin symptoms were the initial manifestations.
Skin rash was most commonly observed in the lower
limbs and foot, followed by thigh, upper limbs, abdomen,
waist-hip, scrotum and face. Twenty-seven cases (38 %)
had rash in more than three affected areas (Fig. 4).
Purpura
Petechiae and ecchymosis were distributed symmetric-
ally interspersed with mild raised skin bumps spots. The
colour was bright crimson to begin with, and then
turned dark and faded over a period of three to ten days.
Three children developed wheal-like rash, necrotizing
purpura, blisters or bullae. 52 (73 %) patients experi-
enced recurrent skin symptoms. Twenty-nine cases
(41 %) relapsed within 1 month, 15 cases recurred within
1 to 3 months (21 %), six cases (8 %) recurred in
3 months to half a year, and two cases (3 %) relapsed
after 8 months and 14 months respectively. 22 cases
(31 %) had a recurrence of skin lesions on more than
three occasions.
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Joint symptoms
Most children developed joint symptoms simultaneously
with rashes or within 11 days of appearance of the rash.
Forty-six cases (65 %) developed joint symptoms after
having had the rash for 1 to 3 days. Nineteen cases
(27 %) experienced the symptoms between 4 and 7 days,
while four cases (6 %) experienced symptoms in the
period between 8 and 11 days.
The joint manifestations included arthritis and arthral-
gia. Some children had sudden onset of symptoms
during resting state. The arthralgia was worsened on
extra weight bearing. A total of 71 (100 %) patients had
arthralgia and discomfort, including 59 patients (83 %)
with joint swelling, three patients (4 %) limited mobility
in the absence of swelling; nine patients (13 %) had
arthralgia only. Distending pain (pain accompanied by a
distending sensation) was reported in 29 cases (41 %),
sore pain (pain with sore and tired discomfort) in 22
cases (31 %), hot pain (hot and painful) [9] in 13 cases
(18 %) and seven cases had indescribable nature of pain
(10 %). Multiple joints were often involved (Fig. 5), and
the pain was migratory and recurring in nature. In 46
cases (65 %), the joint involvement was unilateral, while
25 cases (35 %) had bilateral involvement. A total of 26
cases (37 %) experienced recurrence; 11 cases (15 %)
recurred within 1 month, seven cases (10 %) recurred
within 1 to 3 months, five cases recurred (7 %) within 3
to 6 months, three cases (4 %) relapsed in 6 to
17 months. Joint symptoms occurred simultaneously or
successively with rash during relapse. Thirteen patients
(18 %) relapsed on more than two occasions. However,
the recurrence rate of joint involvement was relatively
low as compared to that of rash. Joint symptoms usually
improved within 1 to 5 days (median, 3 days); 29 cases
improved within 1 to 2 days (41 %), 37 cases (52 %) in 3
to 4 days and five cases (7 %) improved in 5 days.
Gastrointestinal symptoms
Forty patients (56 %) had gastrointestinal symptoms in-
cluding abdominal pain, nausea, vomiting, with diarrhea
or melena on few occasions. Children tended to have
one or more of the above symptoms; 35 children (49 %)
Fig. 2 Seasonal distribution of disease onset showing maximum
cases with onset in autumn and winter
Fig. 3 Predisposing factors for HSP. In 49 % patients, the upper and
lower respiratory tract infection were the triggers
Fig. 1 Age and gender distribution of patients. The majority of patients were 6 to 10 years old, mostly male
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had abdominal pain, 21 (30 %) had vomiting, and 13
cases (18 %) had gastrointestinal bleeding. There were
no cases with intussusception.
Renal involvement
A total of 37 children (52 %) (23 males and 14 females
with ratio at 1.64:1) had signs of renal involvement,
mostly onset within one month of appearance of rash. In
19 cases (27 %), the renal involvement manifested within
15 days of appearance of the rash; in nine cases (13 %)
onset from 16 days and 1 month, in five cases (7 %)
between 1 and 3 months, in three cases (4 %) between
3 months and 1 year, and in one case (1 %) between 1
and 3 years. Renal involvement tended to manifest after
skin symptoms. Proteinuria (11 %) was detected in eight
cases, hematuria in six cases (8 %), concomitant
hematuria and proteinuria in 13 cases (18 %), acute
nephritis in 31 cases (44 %), nephrotic syndrome in 11
cases (15 %), and chronic nephritis in two cases (3 %).
Other symptoms were as follows. Leg edema was
observed in 12 cases (17 %), fever in seven cases (10 %)
(body temperature, 37.5 °C–38.7 °C). Five (7 %) patients
suffered from testicular swelling and pain. Orchitis and
testicular torsion was excluded by ultrasound examin-
ation. Three cases (4 %) had headache and dizziness.
Cranial CT examination showed no abnormalities. In
two cases, there were visible lung shadows which
resolved after treatment.
Laboratory tests
Results of antinuclear antibody, anti-DNA antibodies,
and anti-E NA antibodies tests were negative. Total
leukocytes count was increased in 39 cases (55 %) while
the percentage of neutrophils were increased in 43 cases
(61 %). Platelet counts and coagulation profile were
normal. Occult blood was positive in 35 cases (49 %);
CRP levels were found increased in 19 cases (27 %);
anti-streptolysin O titers were increased in 14 cases
(20 %) and C3 in 18 cases (25 %). IgA, IgG and IgM
were increased in 13 (18 %), 3 (4 %) and one case (1 %),
respectively. D-dimer was found increased in 34 cases
(48 %). Knee effusion was observed on X-ray examination
Table 1 Clinical features of HSP patients with joint
involvements (N = 71)
Symptom N Percent
Skin rash 71 100
Joint manifestations 71 100
Arthritis 62 87
Arthralgias 9 13
Gastrointestinal manifestations 40 56
Abdominal pain 35 49
Vomiting 21 30
Gastrointestinal bleeding 13 18
Renal involvement 37 52
Acute nephritis 31 44
Hematuria and proteinuria 13 18
Nephrotic syndrome 11 15
Proteinuria 8 11
Hematuria 6 8
Chronic nephritis 2 3
Leg edema 12 17
Fever 7 10
Scrotum pain 5 7
Nervous system involvement 3 4
Lung involvement 2 3
Fig. 4 Distribution of skin rash. Foot and lower leg was the most
commonly affected area
Fig. 5 Distribution of affected joints. Knee and ankle joints were the
most frequently affected
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in three patients (4 %). Mesenteric lymph node enlarge-
ment was detected on abdominal ultrasonography in nine
patients (13 %). In patients with upper respiratory tract
infections, throat swab culture yielded beta-hemolytic
streptococci and Staphylococcus aureus in 17 (24 %) and
12 (17 %) cases, respectively.
Misdiagnosis and treatment
In two cases (3 %), joint symptoms appeared 6 and
13 days, respectively, prior to the onset of the rash
and were treated in orthopedics department with
immobilization and anti-infectives. In five (7 %) children
abdominal pain was the first symptom and treated by
anisodamine and cimetidine but with little symptom relief.
A few days later, blood spots and petechiae with arthralgia
appeared. One case (1 %) presented as acute abdomen
pain suggestive of gastrointestinal obstruction. The rash
appeared when the patient was being prepared for surgery.
After consultation with our department, treatment of
80 mg (2 mg/kg per day) methylprednisolone was admin-
istered once a day for 3 days and the symptoms subsided.
General treatments included bed rest, avoidance of
high protein diet and strenuous exercise. Temporary
fasting and nutritional support therapies were advised
for patients with severe gastrointestinal symptoms. Oral
anti-histamine drugs, such as loratadine or cetirizine
was administered. Patients with bacterial infections were
given antibiotics, and leflunomide or tripterygium was
administered in patients with renal involvement.
All 71 patients were treated with corticosteroids, such
as methylprednisolone at 1–2 mg/kg per day as sug-
gested by Joel et al. [10]. The treatment lasted from 1 to
4 weeks and the dosage was gradually reduced after 3 to
5 days, depending on the alleviation of symptoms.
During the corticosteroids treatment, we monitored the
patients for changes in rash, joint symptoms, and gastro-
intestinal manifestations. The average time for rash
dissipation, reduction of joint swelling and pain, and
gastrointestinal symptoms recovery (symptoms of ab-
dominal pain, nausea under control, fecal occult blood
test turned negative) were 5.76 ± 1.72, 2.65 ± 1.08, and
3.25 ± 1.28 days, respectively. Clinical and laboratory pa-
rameters, including BMI, blood pressure, routine blood
test (WBC, RBC, PLT), liver function (ALT, AST) and
kidney function (SCr, BUN) were measured before,
during, and up to 4 weeks after corticosteroid treatment.
Some patients had improvement in these values during
corticosteroids treatment, though not significant
compared to either pre-treatment or post-treatment
(P > 0.05). Also, there was no significant difference in
these values between pre-treatment and post-treatment
periods (P > 0.05). In contrast to previous reports [11],
patients who were treated with corticosteroids had faster
recovery from rashes (t = −10.00, P = 0.00) and joint
swelling and pain (t = −34.62, P = 0.00) than patients
who did not have corticosteroids treatment.
Clinical outcomes
The patients were followed up for 3 years. Fifty-two
cases (73 %) had recurrence of rash. Kidney symptoms,
joint symptoms, gastrointestinal symptoms were re-
curred in 29 cases (41 %), 26 cases (37 %) and 14 cases
(20 %), respectively. Recurrence of abdominal pain,
arthralgia and other symptoms tended to last for a short
time. Some children experienced recurrence after with-
drawal of treatment, episodes of upper respiratory tract
infection or strenuous activity. Among the 37 cases of
HSP nephritis, 19 cases (27 %) of proteinuria and urine
occult blood turned negative within 1 week to 1 month
of incidence, of which urine abnormality was detected in
13 cases (18 %) during first the 2 weeks; in another 15
cases (21 %) urine became normal within 1 month to
1 year and a half; in three cases (4 %) microscopic
hematuria, and proteinuria continued to persist in small
amounts.
On univariate analysis, gastrointestinal symptoms,
increased levels of CRP and D-dimer and scrotal involve-
ment were found to be significantly associated with renal
impairment in HSP children with joint manifestations
(Table 2). On multivariate logistic regression analysis,
scrotal involvement, gastrointestinal symptoms, raised
D-dimer levels were independently associated with
renal impairment in these children (Table 3).
Discussion
HSP has been reported to occur most frequently at age
of 4 to 7 [12, 13] and it has also been reported to onset
at around 6 to 10 years old [8, 14]. Although most
studies have shown a male preponderance [8, 12–15],
but there are reports where greater number of females
has been found to be affected [16, 17]. In the present
study, most of the cases of HSP with joint symptoms
occurred between 6 to 11 years of age, more often in
school-age children than in preschool children, and
more in boys than in girls. This may be due to increased
exposure to various allergens and a higher chance of
contracting infection; especially in boys as they are
generally more active than girls. Infection has been
previously reported as the major predisposing factor for
HSP [6, 12, 13], with most of the cases being reported in
winter, fall and spring. Our data showed that respiratory
tract infection was the major predisposing factor, with
upper respiratory tract infection accounting for 32 %
cases and lower respiratory tract infection accounting
for 17 % cases. In this study, HSP was observed onset
around all seasons with autumn and winter seasons
being the most common. This may be due to dramatic
seasonal temperature changes and children were prone
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to respiratory infections. Disease onset due to strenuous
exercise was less common compared with previous
report [18].
The diagnosis was usually straightforward in patients
presenting with skin purpura as the initial symptom. In
the present study, 90 % of the children developed skin
manifestations at the outset. Most commonly, the rash
first appeared in the lower limbs and foot; and gradually
spread to other limbs. High relapse rate (73 %) was ob-
served within 3 months and subsequently the recurrence
rate gradually declined, which might be due to the
gradual weakening of the aberrant immune response. In
previous studies, rash has been reported to be occurring
mainly in lower limbs and buttocks [9]. Most children
have been reported to develop a recurrent rash within
12 months, with lesions relapsing one to five times, and
late recurrence being associated with milder symptoms
that usually lasted for a short duration [13].
Seventy-one children had varying degrees of joint in-
volvements, which occurred with rash in most patients
or after rash with no specific clinical manifestations.
Patients with joint symptoms as initial manifestations
were easily confused with rheumatoid arthritis, sprains
and etc. However, anti-infection treatment was effective,
which also confirmed HSP with joint symptoms were
associated with infection. Pain, swelling and other symp-
toms sometimes did not occur simultaneously, mostly
occurred as acute arthritis with different nature of pain.
Similar to other studies, we also found that the joint
symptoms frequently occurred in weight bearing large
joints with knee and ankle joints being the most likely to
be affected, since these joints move more and they are
more vulnerable to injuries. In our study, joint symp-
toms could relapse with rash, mostly unilateral, but
Trapani et al. reported that the rash could also be
symmetrical [13].
Abdominal pain, vomiting and gastrointestinal bleed-
ing are the most common symptoms in patients with
HSP [6, 8, 13, 14, 17]. The reported incidence of gastro-
intestinal symptoms could be as high as 34 to 75 %.
However, some reports have indicated gastrointestinal
bleeding as the most common symptom [13, 17] while
in some other reports pain was the most common symp-
tom [13, 14]. In our study, 56 % of all patients had
gastrointestinal symptoms, with abdominal pain being
the most common, followed by vomiting and gastro-
intestinal bleeding. The pain was often periumbilical or
in the upper abdomen as presented as paroxysmal colic.
In our study, 11 % of children had abdominal pain or
arthralgia as the initial clinical presentation, which
resulted in misdiagnosis. Although it was lower than
previously reported [7, 8, 14], in 15 to 25 % of patients,
joint symptoms appeared one week prior to the rash.
Ten to 20 % of these patients have been reported to
present with abdominal pain two weeks prior to the
appearance of rash. Our experience suggests that if
children with abdominal pain or arthralgia are admitted
and develop rash a few days later, the diagnosis of HSP
should be considered. Thus, it is important for the
health care professionals to have adequate knowledge
about HSP so as to avoid unnecessary invasive proce-
dures in such cases.
Renal function is a key determinant of prognosis in
HSP patients. Twenty to 54 % of HSP children may
develop renal involvement [13, 19–21]. Similar to that
reported by Trapani et al., 52 % children in our study had
Table 2 Univariate analysis of risk factors for kidney injury [N (%)]
Risk factor HSP (N = 34) HSPN (N = 37) χ2 P value
Male 17 (50 %) 23 (62 %) 1.07 0.30
Age ≥10 years 9 (26 %) 12 (32 %) 0.30 0.58
Rash≥ 3 areas 11 (32 %) 16 (43 %) 0.89 0.35
Rash recurrence≥ 3 times 8 (24 %) 14 (38 %) 1.70 0.19
Joints recurrence≥ 2 times 5 (15 %) 8 (22 %) 0.57 0.45
Scrotum involvement 1 (3 %) 11 (30 %) 9.05 0.00
Gut involvement 13 (38 %) 27 (73 %) 8.69 0.00
IgA increase 7 (21 %) 12 (32 %) 1.27 0.26
D-dimer increase 9 (26 %) 25 (68 %) 11.99 0.00
CRP increase 5 (15 %) 14 (38 %) 4.84 0.03
CRP C-reaction protein, HSP Henoch-Schönlein purpura, HSPN HSP nephritis
Table 3 Independent predictors of renal damage on
multivariate analysis
Risk factor β P value OR 95 % CI
Scrotum involvement 3.65 0.00 38.42 3.48 - 423.77
Gut involvement 1.63 0.02 5.08 1.28 - 20.10
D-dimer increase 1.41 0.03 4.09 1.18 - 14.23
CRP increase 1.38 0.06 3.99 0.97 - 16.42
CI confidence interval, CRP C-reactive protein, OR Odds ratio
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renal involvement [13] Although the exact mechanism of
pathogenesis is not clear, previous studies have implicated
IgA-containing immune complex deposition in glomeru-
lar basement membrane [4]. The main pathological
changes include mesangial proliferative changes, with
varying degrees of segmental necrosis and glomerular
crescent formation [22] Earlier studies have shown that
HSP nephritis (HSPN) is mostly seen within 1 month,
with some cases occurring within 6 months, and a few
cases appearing after 1 year. Among these cases, 1 to 2 %
of patients may develop irreversible kidney damage [23] In
the present study, 76 % cases developed HSPN within
1 month, with most occurring within 2 weeks. There were
no cases of end-stage renal disease observed during
the 3-year follow up period. The prognosis for HSPN
is good [5, 12, 13].
Our multivariate analysis, scrotal involvement, gastro-
intestinal symptoms and raised D-dimer levels signifi-
cantly correlated with kidney damage. Compared to
patients without these above risk factors, presence of
these factors was associated with 38.42 times, 5.08 times,
4.09 times higher incidence rates, respectively. Tabel et
al. [24] also reported scrotal involvement as a risk factor
for renal impairment. A study Elmas et al. [25] also
showed an association of gastrointestinal symptoms with
kidney damage. Yilmaz et al. [26] reported that D-dimer
levels in HSP patients with renal damage were signifi-
cantly higher than in those without renal involvement.
Similar findings were also reported by another study [27].
In the present study, HSP patients with joint symptoms
readily responded to methylprednisolone treatment. No
long-term side effects were observed and treatment
compliance of patients tended to be good. Not only the ef-
fect of glucocorticoids on joints and abdominal symptoms
in HSP has been confirmed [28, 29], but other studies
have also reported its role in preventing kidney disease
[30, 31]. With timely glucocorticoids in optimal dosage,
adverse reactions tend to be reversible. Titrating the dose
to the severity of the symptoms appears to be the key
paradigm in successful management of children with HSP.
One of the limitations of this study is the relatively small
sample size due to availability of patients. The sample
collection process lasted for 3 years. Due to limitation by
experience and time and space, the present study does not
allow conclusions about therapeutic approaches, which
should be made from prospective controlled studies.
Conclusion
To summarize, HSP with joint involvement most com-
monly occurred in school-aged males during fall and
winter seasons. Upper respiratory tract infection was the
predominant triggering factor. Gastrointestinal symp-
toms, raised D-dimer levels and scrotal involvement
were found to be independently associated with renal
involvement. Rational use of corticosteroids significantly
alleviated the symptoms, with no long-term adverse
effects being observed during follow-up. The present
study does not answer questions including why some pa-
tients experienced joint involvement and others suffered
from gastrointestinal damage and how to explain the
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